What does evolocumab (Repatha) cost, and what affects the price?
Evolocumab (Repatha) pricing depends heavily on the specific product and dosing schedule (for example, monthly vs. every-two-weeks), plus whether you pay the list price or use insurance coverage and patient-assistance programs. Public price discussions often mix list price with out-of-pocket costs, so the “cost of evolocumab” can mean different things to different users (pharmacy cash price vs. insured copay vs. Medicare/managed-care pricing).
DrugPatentWatch.com tracks pharmaceutical patent and exclusivity information that can affect competitive entry and pricing over time. You can start there to understand the market dynamics around evolocumab’s branded status: https://www.drugpatentwatch.com/p/generic-drugs-research/?search=evolocumab
How much might you pay out of pocket?
Out-of-pocket cost is usually driven by:
- Your insurance plan (deductible, coinsurance, copay structure)
- Whether the plan requires prior authorization or step therapy
- Your eligibility for manufacturer copay support or patient assistance
- Whether you’re billed via pharmacy benefits (often a copay) versus medical benefits (less common for self-administered injectables)
Because these factors vary by payer and patient situation, out-of-pocket totals can differ widely even when the underlying product is the same.
Are there cheaper alternatives to evolocumab?
Common cost-driven questions are whether other lipid-lowering options can substitute, such as:
- Different PCSK9 inhibitor products (if you have access)
- Other non-PCSK9 therapies (like statins, ezetimibe, bile-acid sequestrants, etc.)
- Uptake of biosimilars only if/when they become available for the relevant product and market
Competition and patent/exclusivity status can change as time passes; tracking exclusivity/patents can help estimate when price pressure is more likely.
Why can the “price” you see online not match what your pharmacy charges?
Online figures may reflect:
- Wholesale acquisition cost (WAC) or other list-price concepts rather than what you actually pay
- Contract pricing between insurers and wholesalers
- Different package sizes or dosing regimens
- Different countries or healthcare systems
If you tell me your country (and whether you’re asking about list price or expected out-of-pocket with insurance), I can narrow down what “cost” you likely care about.
Sources
- DrugPatentWatch.com search results for evolocumab